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EDITOR – In their very interesting work, Ziaber et al.1
raised  a  question  concerning  involvement  of  poly-
morphonuclear neutrophils (PMNs) in the pathogene-
sis  of  multiple  sclerosis  (MS). Their  results  provide
new and, from the point of view of recent concepts,
rather unusual insights into MS pathogenesis.
We  were  pleased  to  read  this.  In  our  earlier
experiments, we also found some evidence of abnor-
mal  PMN  activation  in  MS.  Moreover,  these  abnor-
malities appeared to be dependent on the interaction
with  autologous  thrombocytes.  We  used  two  test
systems:  the  nonadherent  response  of  leukocytes
elicited  by  calcium  ionophore  A23187;  and,  fur-
thermore,  we  investigated  the  luminol-dependent
chemiluminiscence.
Using  the  ionophore  stimulation,  we  found  that
granulocytes preincubated with autologous thrombo-
cytes  (but  not  granulocytes  alone)  had  increased
nonadherent response in healthy controls. This phe-
nomenon  was  less  expressed  in  MS  patients  and
absent  in  MS  patients  taking  corticosteroids.  We
speculated that these results may reflect a thrombo-
cyte-dependent  alteration  of  adhesive  membrane
properties during the early phase of nonspecific PMN
activation.2 In  the  chemiluminiscence  studies,3 the
addition  of  autologous  thrombocytes  markedly
depressed  both  the  spontaneous  and  the  zymosan-
stimulated  granulocyte  chemiluminiscence  in  MS
patients and in patients with some other neurological
diseases. In healthy controls, this was expressed less
pronouncedly. These findings might indicate an activa-
tion  of thrombocyte suppressive or scavenger func-
tion in MS and some other neurological diseases.
Although  the  PMNs  seem  not  to  be  directly
involved  in  the  demyelination  process  within
the  central  nervous  system,  they  might  play  an
important  part  in  the  complex  interactions  during
vascular and hematogenic processes associated with
immunoactivation in MS. In our opinion, this level of
MS immunopathogenesis deserves greater and more
intensive  attention.
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EDITOR  –  I  agree  with  Dr  Mayer  that  PMN  cells,
especially in the blood of MS patients, are not only
‘the silent observers’. In my study, I have described
the  enhanced  extracellular  markers  expression  on
PMNs  that  might  suggest  priming  of  PMNs  of  the
peripheral blood. In the course of clinically active MS,
the role of PMNs in MS has not yet been shown. Our
study  does not show it  either, thus there is still  an
unsolved problem as to whether these cells play an
important role in the course of MS and how they are
activated.
Dr Mayer suggests, on the basis of his study, that the
changed reactivity of PMNs in the course of MS is due
to  thrombocyte-dependent  alteration  of  the  mem-
brane  properties  during  the  early  phase  of  non-
specific PMNs activation. This cannot be excluded. It
is  worthwhile  to  express  that,  in  both  studies,  Dr
Mayer draws conclusions based on in vitro studies.
Furthermore,  PMNs  were  isolated  from  patients
during different stages of MS activity. In MS patients
without  corticosteroid  treatment,  rather  heteroge-
neous results were obtained, which appears to reflect
the fluctuation in the disease activity. In my opinion,
the  study  would  have  been  more  interesting  if  the
study groups had consisted of MS patients in the same
stage of MS activity.
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